REATA PHARMACEUTICALS INC
DelistedCIK 1358762fmd_02033HJ6HXEVTPGFJ26QBPDWB9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Jun 30, 2023, 35 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 52 | 50 | 50 | 48 | 54 | 27 | 9 | 11 | 2 |
| Research and development | 34 | 35 | 39 | 71 | 97 | 128 | 159 | 156 | 170 |
| Total operating expenses | 48 | 51 | 57 | 95 | 130 | 312 | 235 | 256 | 280 |
| Interest expense | – | – | – | 1 | 6 | 11 | 15 | 7 | 0 |
| Other non-operating income (expense) | 0 | 0 | 0 | (1) | (4) | (5) | (44) | (53) | (34) |
| Income before taxes | 4 | (0) | (7) | (48) | (81) | (290) | (270) | (298) | (312) |
| Income tax expense | 3 | 1 | (0) | 0 | 0 | 0 | (22) | (0) | (0) |
| Net income from continuing operations | 1 | (1) | (6) | (48) | (81) | (290) | (248) | (297) | (312) |
| Net income | 1 | (1) | (6) | (48) | (81) | (290) | (248) | (297) | (312) |